Table 2.
Mortality associated with P. kudriavzevii.
| Author | Year | Study design | Study period | Country | Level of care | Population description | Number of patients | Number of P. kudriavzevii infected patients | Mortality (type, n/n, %) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Bassetti11 | 2011 | Prospective cohort study | Single centre | 01/2008-12/2010 | Italy | Tertiary | Patients with candidaemia | 348 | 9 | 5/9 (55.5%) |
| Kaur12 | 2020 | Retrospective cohort study | Single centre | 01/2014-12/2014 | India | Tertiary | Adult and paediatric patients with candidaemia | 316 (n = 186 paediatric, 130 adults) | 316 | Paediatric patients:17/74 (22.94%), adult patients: not reported |
| Kronen13 | 2018 | Retrospective cohort study | Single centre | 01/2002-01/2015 | United States | Tertiary | Patients with candidaemia | 1873 | 59 | 90-day all-cause mortality for bloodstream infection (BSI): 64.40% |
| Omrani14 | 2014 | Retrospective cohort study | Single centre | 01/2003-12/2012 | Saudi Arabia | Tertiary | Patients with invasive Candida infections | 652 | 9 | 30-day mortality: 4/9 (44%), 90-day mortality: 6/9 (67%) |
| van Schalkwyk15 | 2018 | Retrospective cohort study | Single centre | 01/2012-12/2016 | South Africa | Tertiary | Neonates with bloodstream infections during multiple outbreaks | 589 during the first outbreak | 48 | 7/48 (14.6%) |
| Yacoub16 | 2016 | Retrospective cohort study | Single centre | 01/2001-06/2014 | United States | Tertiary | Cancer patients with candidaemia | 247 | 32 | 19.23% |